Korys’ Post

[#Healthcare] Eurazeo and Kurma Partners, group’s Health venture subsidiary, are thrilled to announce their first co-investment, the second Growth Equity investment of the Nov Santé Actions Non Cotées Fund, in the company PANTERA. As part of this €93m fundraising, both will have a minority stake in the company’s capital alongside EQT Life Sciences, the operation’s lead arranger. 👩🔬 The result of a research partnership initiated in 2019 between IBA (Ion Beam Applications S.A.), specialist in particle acceleration technologies, and the Belgian Nuclear Research Center SCK CEN, PanTera is a company created in 2022 whose goal is to produce Actinium-225 on a large scale. 🔍 This radioisotope shows particularly promising characteristics in the fight against cancer given its ability to eliminate cancer cells more deeply whilst saving as much as possible of the healthy surrounding tissues. Numerous clinical trials are underway in the treatment of certain cancers and leukemia, notably neuroendocrine and prostate cancers. 🏥 The co-investment between Nov Santé Actions Non Cotées and Kurma Partners reaffirms the Eurazeo group’s leadership in the strategic healthcare sector. This joint investment in PanTera marks a new phase in the consolidation of sector expertise to support innovation and growth in healthcare companies in Europe. 📰 Read more: https://lnkd.in/e9CwUGdd #Healtheconomy #Cancertreatment #Investment #Radiopharmaceuticals Sven Van den Berghe Christophe Malice Samy Bertrand Olivier MILLET Arnaud Vincent Asnen Cassam-Chenaï Simon Mauclair Samantha Schwartz Hugo Pergher Nicolas Lelièvre Rémi Droller Thierry Laugel Jean-Francois Rivassou Maÿlis Deschamps Daniel Parera Philippe Peltier

Just completed: A report on The State of the Mitochondria Portion of the Aging Biotech Field https://lnkd.in/gdmsKtNt 50 companies! $1.4+B raised 700+ people 150+ clinical trials Many MoAs/targets: mitophagy, transplant, fission, NAD+, UrolithinA, CD38, PINK1, PPARδ, DRP1, USP30, Complex 1, OMA1, & more. A sortable clinical pipeline table summarizing the aggregate pipeline for the entire sub-sector, with company links, is introduced & linked. This is also a sneak preview of part of the big in-progress update/overhaul of AgingBiotech.info's companies table, which is now ~40-50% done overall. Everything described in this thread comes directly from this database. The full new version will replace the current list when closer to 100% done. Feedback welcomed. Any important aging-relevant mitochondria companies missing?

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round. 📣 Led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures , Inkef Capital, Vi Partners, Schroders Capital and 3B Future Health Fund I & II, this funding highlights a shared vision for the potential of our portfolio of precision oral small molecules.   This significant funding will:   🚀 Accelerate development of #roginolisib for the treatment of #uvealmelanoma through a randomized Phase II study 🚀 Broaden development of roginolisib for other cancer indications, including randomized Phase II studies in #NSCLC and primary #myelofibrosis 🚀 Progress #cambritaxestat and IOA-359 programs   Watch this space as we kick off a number of Phase II studies later in 2024.   Thank you to the team, investors and collaborators who continue to support and drive iOnctura forward. Link to press release in comments ⬇ #financing #oncology #drugdevelopment

Transitioning from cobalt-60 teletherapy devices to linear accelerators requires investment and commitment. Acquiring and installing a Linacs device is costly and complex, requiring active support from the regulator, medical facility and other stakeholders. Senegal overcame these challenges to become a leader in cancer treatment in the region. See the full story: https://lnkd.in/eTxz7WhW

⚡ Exciting developments at Nuclidium as we prepare for LSX - partnering for Life Science eXecutives! ⚡ Investments by industry giants like Lilly and BMS highlight the potential and competitive nature of the radiopharmaceutical sector. Here’s why you should meet with Leila Jaafar and Andreas Schuh on the 29th and 30th of April in London: ✅ Innovative Theranostics: Our Cu-61 and Cu-67 pairs offer precise diagnosis and targeted treatment, improving efficacy and minimizing side effects for major cancers such as breast, prostate, lung, and pancreatic. ✅ Advanced Diagnostics: Cu-61’s longer half-life and superior properties simplify manufacturing and extend usability, enhancing diagnostic applications. ✅ Effective Therapeutics: Cu-67 aligns perfectly with our targeting molecules, allowing for higher tumor dosage with reduced toxicity and shorter hospital stays. ✅ Sustainable Production: In collaboration with LinaThera, our proprietary, scalable production facilities are independent of nuclear reactors, beginning in Germany with plans for global expansion. With commitments secured and a strategic investor on board, we're gearing to close Series A2 in Q3. Join us at LSX - partnering for Life Science eXecutives to discover how our cutting-edge solutions are poised to revolutionize cancer treatment. #LSX #Radiopharmaceuticals #InvestInInnovation #LinaThera #Nuclidium

EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PANTERA, which aims to accelerate global actinium-225 production. The oversubscribed EUR 93 million equity round marks the largest Series A funding round ever in Life Science in Belgium, a testament to the company's vision and execution plan. EQT Life Sciences is joined in this investment by Kurma Partners, Eurazeo, Paladin Asset Management, Korys, and PMV as followers. With additional equity and debt funding, the total amount raised is EUR 134 million. PanTera is now fully funded to complete its game-changing venture, enabling the large-scale, dependable supply of Actinium-225 in time for the anticipated commercialization of Actinium-based radiopharmaceuticals. EQT Life Sciences wants to express its gratitude to the existing shareholders, SCK CEN, IBA, and SFPIM, as well as to its legal advisor, A&O Shearman. https://lnkd.in/egcv-VYm #actinium #radiopharmaceuticals #TAT #isotopeha #radioisotope #nuclear #medicine

Don't miss out on catching up with Imugene's Head of Corporate Development, Dr. Nicholas Ede, as he shares insightful perspectives from the recent ASX Small and Mid-Cap Conference. Watch the complete presentation to gain valuable insights: https://lnkd.in/gk2qBwns #IMU #Imugene #OncolyticVirotherapy #CancerResearch #Innovation #cancer #biotech #InvestmentOpportunity

Today we celebrate our new partnership with Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of advancing a small molecule condensate modulator (#cmod) that corrects an underlying pathology shared by ~97 % of all ALS patients: the mislocalization of the TDP-43 splicing factor into aberrant cytoplasmic condensates. Our expertise in #condensate science will complement MTPC’s unrivaled expertise in ALS drug development to progress a c-mod discovered in house using our proprietary platform. 🔬 The c-mod selectively restores nuclear localization of TDP-43, promotes neuronal health in in vitro pre-clinical models, and demonstrated improvement of multiple ALS biomarkers in in vitro and in vivo preclinical models.  Read more about the science and financial details of this exciting new milestone here: https://lnkd.in/ghWguxv5  

Congratulations to our client, Mountain Crest Acquisition Corp. V (Nasdaq: MCAG), on their business combination agreement with CUBEBIO!                                                                                                                                            Mountain Crest V (Nasdaq: MCAG) has entered into a definitive agreement to bring CUBEBIO, an innovative in-vitro diagnostic company, to the public markets. CUBEBIO's groundbreaking technology, which uses a non-invasive urine test to detect cancer at an early stage, represents a significant advancement in cancer screening.    The transaction, valued at $375 million, is expected to close in Q1 2025, and will propel CUBEBIO towards global expansion and increased corporate value. This is another milestone for Mountain Crest V as they continue their success in SPAC business combinations. We extend our congratulations to Dr. Suying Liu, PhD, Chairman and CEO of Mountain Crest V, and Eun-jong Choi, CEO of CUBEBIO, for their leadership in this transformative deal.    https://lnkd.in/emZgfyK7    #MountainCrestV #CUBEBIO #SPAC #BusinessCombination #CapitalMarkets #CancerDiagnostics #Innovation #CalabreseConsulting #Nasdaq #MCAG Calabrese Consulting LLC

Epoch 49: Sweat Equity - Your Weekly Biotech News Fix The Week of 12/2 Designed to be consumed as a quick scroll 👉 $BIOA Apelin program crash & burn 👉 $JANX breakthrough in solid tumor TCE 👉 Atlas raises a new biotech fund 👉 $GSK deals in neuro and China ADCs 👉 Trump picks impact analysis https://lnkd.in/dEkBy2bY